基于神经母细胞瘤123碘标记碘代苄胍SPECT/CT的影像基因组学研究

神经母细胞瘤（NB）是儿童期最常见的颅外实体恶性肿瘤；肿瘤具有明显异质性，疾病危险度分层、疗效评估和预后预测对进一步诊治至关重要，目前的危险度分层主要基于病理结果，但获取病理组织有一定创伤性及风险、且目前的疗效评估标准有较大的主观性；因此如能基于影像对NB进行无创性危险度分层、疗效评估与预后预测，将对NB的精准诊治起到非常重要的作用。我们前期研究显示基于PET/CT的影像组学可准确预测NB的危险度、骨髓转移，但18F-FDG 在NB特异性差、辐射剂量及价格较高，不是国际指南推荐的NB首选核医学功能显像方法，而123I-MIBG SPECT/CT是国际指南推荐首选的分子影像方法。因此本研究欲通过基于123I-MIBG的影像组学，①建立危险度分层（MYCN、PHOX2B、TERT、1p与11q）的预测模型；②建立疗效预测的模型；③建立预后预测的模型，为NB的精准诊疗t及机制研究提供依据。

Neuroblastoma (NB) is the most common extracranial solid malignant tumor in childhood. NB has obvious heterogeneity. Risk stratification, therapy response evaluation, and prognosis prediction are essential for further accurate diagnosis and treatment of NB. However, the current risk stratification was based on pathological results. The process of acquiring the pathological tissue was an invasive associated with some risk. The evaluation criteria for therapy response are subjective. Therefore, if NB patients can be noninvasively stratified based on images, evaluation of curative effect and prognosis prediction. It will be helpful for accurate diagnosis and personal treatment of NB. Our previous studies showed that radiomics based on 18F-FDG PET/CT could predict the risk of NB and whether or not bone marrow metastasis, but 18F-FDG has lower specificity in NB, higher radiation dose, and higher price compared with 123I-MIBG SPECT/CT. 18F-FDG PET/CT is not the recommended nuclear medicine scan by international NB guidelines. 123I-MIBG SPECT/CT is the preferred molecular imaging method recommended by international guidelines. Therefore, ①this study intends to establish a prediction model for risk stratification (MYCN, PHOX2B, TERT, 1p and 11q) through radiomics based on 123I-MIBG SPECT/CT; ② establish a model for predicting therapy response; ③ establish a model for prognosis prediction, which is important for precise diagnosis and personal treatment, mechanism research of NB.